Healthcare insurance company Molina Healthcare (NYSE: MOH) met Wall Street’s revenue expectations in Q2 CY2026, but sales fell by 4.8% year on year to $10.87 billion. On the other hand, the company’s full-year revenue guidance of $42 billion at the midpoint came in 5.1% below analysts’ estimates. Its non-GAAP profit of $1.51 per share was 7.8% above analysts’ consensus estimates.

Is now the time to buy Molina Healthcare? Find out by accessing our full research report, it’s free.

Company Overview

Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare (NYSE: MOH) provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states.

Revenue Growth

A company’s long-term sales performance can indicate its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Over the last five years, Molina Healthcare grew its sales at a solid 13.7% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers, a helpful starting point for our analysis.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Molina Healthcare’s annualized revenue growth of 9.1% over the last two years is below its five-year trend, but we still think the results were respectable.

We can dig further into the company’s revenue dynamics by analyzing its number of customers, which reached 4.93 million in the latest quarter. Over the last two years, Molina Healthcare’s customer base averaged 3.8% year-on-year declines. Because this number is lower than its revenue growth, we can see the average customer spent more money each year on the company’s products and services.

This quarter, Molina Healthcare reported a rather uninspiring 4.8% year-on-year revenue decline to $10.87 billion of revenue, in line with Wall Street’s estimates.

Looking ahead, sell-side analysts expect revenue to grow 4.9% over the next 12 months, a deceleration versus the last two years. This projection doesn’t excite us and indicates its products and services will see some demand headwinds. At least the company is tracking well in other measures of financial health.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

Adjusted Operating Margin

Molina Healthcare was profitable over the last five years but held back by its large cost base. Its average adjusted operating margin of 3.7% was weak for a healthcare business.

Analyzing the trend in its profitability, Molina Healthcare’s adjusted operating margin decreased by 3.3 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 3.7 percentage points. We still like Molina Healthcare but would like to see some improvement in the future.

In Q2, Molina Healthcare generated an adjusted operating margin profit margin of 1.6%, down 2.1 percentage points year on year. This contraction shows it was less efficient because its expenses increased relative to its revenue.

Earnings Per Share

We track the long-term change in earnings per share (EPS) for the same reason as long-term revenue growth. Compared to revenue, however, EPS highlights whether a company’s growth is profitable.

Sadly for Molina Healthcare, its EPS declined by 27.3% annually over the last five years while its revenue grew by 13.7%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes.

We can take a deeper look into Molina Healthcare’s earnings to better understand the drivers of its performance. As we mentioned earlier, Molina Healthcare’s adjusted operating margin declined by 3.3 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; interest expenses and taxes can also affect EPS but don’t tell us as much about a company’s fundamentals.

In Q2, Molina Healthcare reported adjusted EPS of $1.51, down from $5.48 in the same quarter last year. Despite falling year on year, this print beat analysts’ estimates by 7.8%. Over the next 12 months, Wall Street expects Molina Healthcare’s full-year EPS to grow 127% from $2.95 to $6.71.

Key Takeaways from Molina Healthcare’s Q2 Results

It was encouraging to see Molina Healthcare beat analysts’ full-year EPS guidance expectations this quarter. We were also glad its EPS outperformed Wall Street’s estimates. On the other hand, its full-year revenue guidance missed. Overall, this quarter could have been better. The stock traded down 6.6% to $207.00 immediately following the results.

Molina Healthcare didn’t show its best hand this quarter, but does that create an opportunity to buy the stock right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here (it’s free).